X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14) 14
humans (13) 13
female (11) 11
hematology, oncology and palliative medicine (11) 11
oncology (11) 11
cancer (10) 10
middle aged (10) 10
ovarian cancer (10) 10
aged (8) 8
clinical trials (8) 8
disease-free survival (8) 8
ovarian neoplasms - pathology (8) 8
treatment outcome (8) 8
analysis (7) 7
ovarian neoplasms - drug therapy (7) 7
cancer therapies (6) 6
chemotherapy (6) 6
tumors (6) 6
adult (5) 5
bevacizumab (5) 5
care and treatment (5) 5
mutation (5) 5
neoplasm staging (5) 5
ovarian neoplasms - mortality (5) 5
patients (5) 5
quality of life (5) 5
time factors (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
follow-up studies (4) 4
medical prognosis (4) 4
open-label (4) 4
paclitaxel - administration & dosage (4) 4
abdomen (3) 3
abridged index medicus (3) 3
angiogenesis (3) 3
brca1 protein - genetics (3) 3
brca2 protein - genetics (3) 3
breast cancer (3) 3
carboplatin - administration & dosage (3) 3
carcinoma (3) 3
carcinoma, ovarian epithelial (3) 3
deoxyribonucleic acid--dna (3) 3
disease progression (3) 3
diseases (3) 3
drug administration schedule (3) 3
drug therapy (3) 3
epithelial ovarian (3) 3
medicine, general & internal (3) 3
neoplasm grading (3) 3
neoplasm recurrence, local - drug therapy (3) 3
neoplasms - therapy (3) 3
neoplasms, glandular and epithelial - drug therapy (3) 3
ovarian neoplasms - genetics (3) 3
poly polymerase (3) 3
prognosis (3) 3
quality-of-life (3) 3
relapse (3) 3
research (3) 3
solid tumors (3) 3
survival rate (3) 3
administration, oral (2) 2
aged, 80 and over (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
articles (2) 2
biomarkers (2) 2
breast-cancer (2) 2
canada (2) 2
cancer patients (2) 2
chronic illnesses (2) 2
combination (2) 2
double-blind method (2) 2
enzyme inhibitors - administration & dosage (2) 2
enzyme inhibitors - adverse effects (2) 2
fallopian tube neoplasms - drug therapy (2) 2
gene mutations (2) 2
health aspects (2) 2
heterozygosity (2) 2
homologous recombination (2) 2
homology (2) 2
hospitals (2) 2
liposomal doxorubicin (2) 2
male (2) 2
medical research (2) 2
monosaccharides (2) 2
multicenter (2) 2
neoplasm recurrence, local (2) 2
neoplasm recurrence, local - pathology (2) 2
neoplasms - mortality (2) 2
neoplasms - pathology (2) 2
neoplasms, glandular and epithelial - pathology (2) 2
olaparib maintenance therapy (2) 2
oncology, experimental (2) 2
ovarian carcinoma (2) 2
ovarian neoplasms - enzymology (2) 2
palliative care (2) 2
patient-reported outcomes (2) 2
peritoneal neoplasms - drug therapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 928 - 936
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | LIPOSOMAL DOXORUBICIN | MULTICENTER | INHIBITION | SOLID TUMORS | CISPLATIN | ONCOLOGY | POLYMERASE | OPEN-LABEL | COMBINATION | CARCINOMA | MAINTENANCE THERAPY | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer
Journal Article
by Coleman, Robert L and Coleman, R L and Oza, Amit M and Oza, A M and Lorusso, D and Lorusso, Domenica and Aghajanian, C and Aghajanian, Carol and Oaknin, A and Oaknin, Ana and Dean, A and Dean, Andrew and Colombo, N and Colombo, Nicoletta and Weberpals, Johanne I and Weberpals, J I and Clamp, Andrew and Clamp, A and Scambia, Giovanni and Scambia, G and Leary, A and Leary, Alexandra and Holloway, Robert W and Holloway, R W and Gancedo, M Amenedo and Gancedo, Margarita Amenedo and Fong, Peter C and Fong, P C and Goh, Jeffrey C and Goh, J C and O'Malley, David M and O'Malley, D M and Armstrong, Deborah K and Armstrong, D K and Garcia-Donas, Jesus and Garcia-Donas, J and Swisher, E M and Swisher, Elizabeth M and Floquet, A and Floquet, Anne and Konecny, Gottfried E and Konecny, G E and McNeish, I A and McNeish, Iain A and Scott, C L and Scott, Clare L and Cameron, Terri and Maloney, Lara and Isaacson, Jeff and Goble, Sandra and Grace, Caroline and Harding, Thomas C and Raponi, Mitch and Sun, James and Lin, Kevin K and Giordano, Heidi and Ledermann, J A and Ledermann, Jonathan A and Buck, M and Friedlander, M L and Harnett, P and Kichenadasse, G and Denys, H and Dirix, L and Vergote, I and Elit, L and Ghatage, P and Plante, M and Provencher, D and Welch, S and Gladieff, L and Joly, F and Lortholary, A and Lotz, J and Medioni, J and Tredan, O and You, B and El-Balat, A and Hänle, C and Krabisch, P and Neunhöffer, T and Pölcher, M and Wimberger, P and Amit, A and Kovel, S and Leviov, M and Safra, T and Shapira-Frommer, R and Stemmer, S and Bologna, A and Pignata, S and Sabbatini, R F and Tamberi, S and Zamagni, C and O'Donnell, A and Herraez, A Casado and Guerra, E M and Palacio, I and Romero, I and Sanchez, A and ... and ARIEL3 Investigators and ARIEL3 investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10106, pp. 1949 - 1961
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a mutation or high percentage of... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | SOLID TUMORS | BEVACIZUMAB | OPEN-LABEL | CANCER | HETEROZYGOSITY | EPITHELIAL OVARIAN | CHEMOTHERAPY | Double-Blind Method | Follow-Up Studies | Risk Assessment | Humans | Middle Aged | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Survival Rate | Treatment Outcome | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Indoles - administration & dosage | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Neoplasm Recurrence, Local - pathology | Disease-Free Survival | Maintenance Chemotherapy - methods | Internationality | Ovarian Neoplasms - therapy | Female | Aged | Molecular Targeted Therapy - methods | Clinical trials | Care and treatment | Carcinoma | Drug therapy | Ovarian cancer | Cancer | Analysis | Chemotherapy | Ovarian carcinoma | Platinum | Biomarkers | Mutation | Cancer therapies | Tumors | Homologous recombination | Central nervous system | Poly(ADP-ribose) | Homology | Genomes | Fallopian tube | ADP | Anticancer properties | Metastases | Homologous recombination repair | Randomization | Pain | Motivation | Ribose | Hemoglobin | Alanine | Anemia | Poly(ADP-ribose) polymerase | Breast cancer | Patients | Survival | Heterozygosity | Abdomen | Polymerase | Inhibitors | Point mutation | Loss of heterozygosity | Antitumor activity | Aspartate aminotransferase | Peritoneum
Journal Article
by Sieh, Weiva, PhD and Köbel, Martin, Dr and Longacre, Teri A, Prof and Bowtell, David D, Prof and deFazio, Anna, PhD and Goodman, Marc T, PhD and Høgdall, Estrid, PhD and Deen, Suha, Prof and Wentzensen, Nicolas, MD and Moysich, Kirsten B, Prof and Brenton, James D, MD and Clarke, Blaise A, MD and Menon, Usha, Prof and Gilks, C Blake, Prof and Kim, Andre, MPH and Madore, Jason, MS and Fereday, Sian, BSc and George, Joshy, MEng and Galletta, Laura, BSc and Lurie, Galina, MD and Wilkens, Lynne R, DrPH and Carney, Michael E, MD and Thompson, Pamela J, MPH and Matsuno, Rayna K, PhD and Kjær, Susanne Krüger, Prof and Jensen, Allan, PhD and Høgdall, Claus, Prof and Kalli, Kimberly R, PhD and Fridley, Brooke L, PhD and Keeney, Gary L, MD and Vierkant, Robert A, MS and Cunningham, Julie M, PhD and Brinton, Louise A, PhD and Yang, Hannah P, PhD and Sherman, Mark E, MD and García-Closas, Montserrat, Prof and Lissowska, Jolanta, PhD and Odunsi, Kunle, Prof and Morrison, Carl, MD and Lele, Shashikant, Prof and Bshara, Wiam, MD and Sucheston, Lara, PhD and Jimenez-Linan, Mercedes, MD and Driver, Kristy, BSc and Alsop, Jennifer, BA and Mack, Marie and McGuire, Valerie, PhD and Rothstein, Joseph H, MS and Rosen, Barry P, Prof and Bernardini, Marcus Q, MD and Mackay, Helen, MD and Oza, Amit, Prof and Wozniak, Eva L, BSc and Benjamin, Elizabeth, MD and Gentry-Maharaj, Aleksandra, PhD and Gayther, Simon A, Prof and Tinker, Anna V, MD and Prentice, Leah M, PhD and Chow, Christine, BMLSc and Anglesio, Michael S, PhD and Johnatty, Sharon E, PhD and Chenevix-Trench, Georgia, Prof and Whittemore, Alice S, Prof and Pharoah, Paul DP, Prof and Goode, Ellen L, PhD and Huntsman, David G, Prof and Ramus, Susan J, PhD
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 853 - 862
Journal Article